OTCMKTS:PFSCF - ProMetic Life Sciences Stock Price, News, & Analysis

$0.0208
0.00 (0.00 %)
(As of 06/14/2019 04:00 PM ET)
Today's Range
$0.0208
Now: $0.0208
$0.0208
50-Day Range
$0.02
MA: $0.03
$0.05
52-Week Range
$0.0178
Now: $0.0208
$0.75
Volume8,000 shs
Average Volume106,829 shs
Market Capitalization$15.37 million
P/E RatioN/A
Dividend YieldN/A
Beta3.08
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PFSCF
Previous SymbolNASDAQ:PFSCF
CUSIPN/A
CIKN/A
Phone1-450-781-0115

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.55 million
Book Value($0.07) per share

Profitability

Net Income$-150,730,000.00
Net Margins-373.05%

Miscellaneous

Employees487
Market Cap$15.37 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for PFSCF and its competitors with MarketBeat's FREE daily newsletter.

ProMetic Life Sciences (OTCMKTS:PFSCF) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the OTCMKTS under the ticker symbol "PFSCF."

How were ProMetic Life Sciences' earnings last quarter?

ProMetic Life Sciences Inc. (OTCMKTS:PFSCF) issued its earnings results on Monday, April, 1st. The company reported $0.01 earnings per share for the quarter. The company earned $8.02 million during the quarter. ProMetic Life Sciences had a negative return on equity of 3,350.55% and a negative net margin of 373.05%. View ProMetic Life Sciences' Earnings History.

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

News coverage about PFSCF stock has trended somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProMetic Life Sciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the near future. View News Stories for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

What other stocks do shareholders of ProMetic Life Sciences own?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PFSCF stock can currently be purchased for approximately $0.0208.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of $15.37 million and generates $36.55 million in revenue each year. ProMetic Life Sciences employs 487 workers across the globe.View Additional Information About ProMetic Life Sciences.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://www.prometic.com/.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115 or via email at [email protected]


MarketBeat Community Rating for ProMetic Life Sciences (OTCMKTS PFSCF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PFSCF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFSCF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/15/2019 by MarketBeat.com Staff

Featured Article: Hedge Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel